Physician profile
Intisar Ibrahim
NPI 1912335191
$1,978.57
in general payments reported to CMS, 2019-2025
16 companies · $15.45 in 2025
The $15.45 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $257 · 2023: $938 · 2024: $270 · 2025: $15.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.34 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $409.03 | 2021-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.03 | 2023-2024 | Caplyta |
| Mannkind Corporation | $185.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $170.00 | 2022-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $135.13 | 2023 | Ingrezza |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Axsome Therapeutics, INC. | $33.05 | 2023 | Auvelity |
| Sunovion Pharmaceuticals INC. | $32.29 | 2021-2022 | |
| Horizon Therapeutics Plc | $14.71 | 2021 | |
| Celgene Corporation | $14.20 | 2023 | Reblozyl |
| Tris Pharma INC | $14.08 | 2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $13.79 | 2023 | Hetlioz, Fanapt |
| Alkermes, INC. | $12.89 | 2023 | Aristada, Lybalvi |
| Almatica Pharma LLC | $12.75 | 2023 | Loreev Xr, Sertraline Hcl |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $9.30 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Intisar Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.